184948-23-0

Basic information

• Product Name: Pentanoic acid, 2-bromo-4-methyl-, phenylmethyl ester, (2R)-
• CAS NO: 184948-23-0
• Molecular Formula: C13H17BrO2
• Molecular Weight: 285.181
• Mol File: 184948-23-0.mol

Chemical Properties

• CAS DataBase Reference: Pentanoic acid, 2-bromo-4-methyl-, phenylmethyl ester, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanoic acid, 2-bromo-4-methyl-, phenylmethyl ester, (2R)-(184948-23-0)
• EPA Substance Registry System: Pentanoic acid, 2-bromo-4-methyl-, phenylmethyl ester, (2R)-(184948-23-0)

Safety Data

• Hazardous Substances Data: 184948-23-0(Hazardous Substances Data)

Upstream product

• 42990-28-3 (R)-2-bromo-4-methylpentanoic acid 
• 100-51-6 benzyl alcohol 
• 328-38-1 (R)-leucine 
• 28659-87-2 2-Bromo-4-methylpentanoic Acid 
• 81927-55-1 O-benzyl 2,2,2-trichloroacetimidate 

Downstream Products

• 184948-24-1 tert-butyl (2R)-1,2-dibenzyl 4-methylpentane-1,1,2-tricarboxylate 
• 228261-86-7 dibenzyl 3(RS)-tert-butyloxycarbonyl-3-cinnamyl-2(R)-iso-butylsuccinate 
• 219615-70-0 3(S)-tert-butyloxycarbonyl-6-phenyl-2(R)-isobutylhexanoic acid 
• 484685-77-0 tert-butyl 3(R)-hydroxymethyl-5-methyl-2(S)-phenylpropylhexanoate 

Relevant articles and documents

Enantioselective protonation of α-hetero carboxylic acid-derived ketene disilyl acetals under chiral ionic Bronsted acid catalysis

Highly enantioselective protonation of α-halo and alkoxy carboxylic acid-derived ketene disilyl acetals is achieved by using P-spiro chiral diaminodioxaphosphonium barfate as a Bronsted acid catalyst, where the enantiofacial discrimination by the catalyst mainly stems from the recognition of the electronic difference between two substituents on the ketene disilyl acetal.

Solid-phase synthesis of succinylhydroxamate peptides: Functionalized matrix metalloproteinase inhibitors

A novel solid-phase synthesis strategy toward succinylhydroxamate peptides, using an appropriately protected hydroxamate building block, is described. Rapid and efficient access is gained to amine-functionalized peptides, which can be decorated with, for instance, a fluorescent label. In addition, we demonstrate an on-resin synthesis of a biotinylated photoactivatable hydroxamate peptide, which can be used as an activity-based probe for matrix metalloproteinases and ADAMs.

NOVEL HYDROXAMIC ACID DERIVATIVES

Disclosed are compounds which have not only potent metalloproteinase-inhibiting activity but also amazingly excellent bioavailability and biological activity invivo, including the property of being well absorbed via oral routes, thereby serving as useful pharmaceuticals, intermediates and processes for the production thereof. The disclosed compounds of the formula (I): wherein R1 is hydrogen, or a hydroxy-protecting group; R2 is hydrogen, or an amino-protecting group; R3, R7, and R8, which may be identical or different, are each independently hydrogen, hydroxy, unsubstituted or optionally substituted (C1-C6) alkyl, or unsubstituted or optionally substituted aryl-(C1-C6) alkyl; R4 is unsubstituted or optionally substituted (C1-C6) alkyl, or unsubstituted or optionally substituted aryl-(C1-C6) alkyl; R5 is hydrogen, unsubstituted or optionally substituted alkyl, unsubstituted or optionally substituted aralkyl, or a carboxy-protecting group; R6 is hydrogen, hydroxy, amino, and a group of the formula: -X-Y wherein X is oxygen, (C1-C6) alkylene or phenylene, Y is a group of the formula: -A-B or -B, wherein A is (C1-C6) alkylene, imino, and (C1-C6) alkyleneimino, and B is hydrogen, amino, amidino, sulfonyl, acylimidoyl, unsubstituted or optionally substituted imidazolyl, unprotected or optionally protected bis(phosphono)methyl or unprotected or optionally protected bis(phosphono)hydroxymethyl; or salts thereof are useful for pharmaceutical and/or veterinary compositions, particularly as metalloproteinase inhibitors which inhibit matrix metalloproteinases or tumor necrosis factor-α-converting enzymes (TNF-α convertases).

Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model.

A new series of succinate-based dual inhibitors against matrix metalloproteinases (MMPs) and tumor necrosis factor alpha converting enzyme (TACE) possessing highly-water solubility was designed, synthesized, and evaluated for enzyme inhibition. Incorporat

NOVEL REMEDIES FOR ALLERGIC DISEASES

Disclosed are anti-inflammatory agents, antiallergic agents, particularly prophylactically and/or therapeutically effective drugs for type I and/or IV allergic conditions, and further pharmaceutical drugs for prophylactically and/or therapeutically treating bronchial asthma, atopic diseases, etc. The inventive drugs comprising a prophylactically and/or therapeutically effective amount of a hydroxamic acid derivative are active in the prophylaxis and/or therapy of allergy, especially type I and/or IV allergy, etc. The drugs are active in prophylactically and/or therapeutically treating inflammation, rhinitis, conjunctivitis, bronchial asthma, atopic diseases (including dermatitis, enteritis, etc.), or allergic gastroenterocolitis (allergic inflammation in digestive tract). The application of such drugs leads to (A) reduction of cells (such as lymphocytes, neutrophils, mast cells, eosinophils, basophils, macrophages and monocytes) at a diseased site, and/or (B) alleviation of inflammatory symptoms caused by migration, infiltration or accumulation of cells (such as lymphocytes, neutrophils, mast cells, eosinophils, basophils, macrophages and monocytes) to (or at) the diseased site, (C) inhibition of pathophysiological functions in cells (such as lymphocytes, neutrophils, mast cells, eosinophils, basophils, macrophages, monocytes, Langerhans cell and dendritic cells), and/or (D) reducing the blood level or inhibiting the production, of antibodies, especially IgE. Accordingly, the drugs are useful in the prophylaxis and/or therapy of diseases, disorders or ill conditions at the site.